Applied Therapeutics, Inc. Stock price

Equities

APLT

US03828A1016

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
6.8 USD -0.73% Intraday chart for Applied Therapeutics, Inc. -0.37% +102.99%
Sales 2024 * 10.54M Sales 2025 * 68.12M Capitalization 725M
Net income 2024 * -70M Net income 2025 * -17M EV / Sales 2024 * 48.9 x
Net cash position 2024 * 210M Net cash position 2025 * 170M EV / Sales 2025 * 8.15 x
P/E ratio 2024 *
-9.71 x
P/E ratio 2025 *
-20.8 x
Employees 25
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.09%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Applied Therapeutics, Inc.

1 day-0.73%
1 week-1.45%
Current month-4.49%
1 month+21.86%
3 months+116.56%
6 months+157.58%
Current year+102.99%
More quotes
1 week
6.49
Extreme 6.49
7.39
1 month
5.36
Extreme 5.36
7.72
Current year
1.85
Extreme 1.85
9.39
1 year
0.76
Extreme 0.7571
9.39
3 years
0.50
Extreme 0.4995
25.59
5 years
0.50
Extreme 0.4995
57.39
10 years
0.50
Extreme 0.4995
57.39
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 16-01-19
Director of Finance/CFO 55 16-05-31
Chief Operating Officer 57 Dec. 27
Members of the board TitleAgeSince
Director/Board Member 77 19-03-31
Director/Board Member 76 16-12-31
Director/Board Member 66 17-02-28
More insiders
Date Price Change Volume
24-03-28 6.8 -0.73% 1,551,492
24-03-27 6.85 +2.70% 676,165
24-03-26 6.67 -1.19% 563,300
24-03-25 6.75 0.00% 635,484
24-03-22 6.75 -1.10% 1,092,712

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.8 USD
Average target price
11.6 USD
Spread / Average Target
+70.59%
Consensus
  1. Stock
  2. Equities
  3. Stock Applied Therapeutics, Inc. - Nasdaq